Divi's Laboratories Ltd.

NSE: DIVISLAB · Healthcare

₹10,320.50+1.78%06 Nov 2026

Ask the data

Instant answers about Divi's Laboratories Ltd. — computed from its filings, no language model

Market cap₹2,73,493 cr

Current price₹10,320.50

High / Low₹10,320 / ₹5,821

P/E93.5

P/B16.32

Book value₹632.5

ROE17.5%

ROCE23.0%

Debt / equity0.00

Dividend yield0.29%

EPS (TTM)₹110.38

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY20	FY21	FY22	FY23	FY24	FY26
Revenue	5,394	6,969	8,960	7,768	7,845	10,560
EBITDA	1,822	2,860	3,882	2,368	2,205	3,441
Operating margin	33.8%	41.0%	43.3%	30.5%	28.1%	32.6%
Interest	6	1	1	1	3	23
Depreciation	186	256	312	343	378	463
Profit before tax	1,819	2,666	3,684	2,369	2,163	3,388
Tax	443	682	723	545	563	820
Net profit	1,377	1,984	2,960	1,823	1,600	2,568
EPS ₹	51.85	74.75	111.52	68.69	60.27	96.75
Operating cash flow	—	—	1,912	2,460	1,261	2,738
Capex	—	—	713	473	1,003	2,520
Dividend paid	—	—	531	796	796	797
Total assets	8,536	10,774	13,375	14,439	15,470	20,033
Equity	7,310	9,295	11,728	12,767	13,571	16,761

Quarterly performance

last 28 quarters · ₹ crore

showing latest 8 of 28 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
Revenue	1,163	1,446	1,396	1,390	1,730	1,749	1,701	1,788	1,961	1,988	2,493	2,518	2,255	1,855	1,708	1,951	1,778	1,909	1,855	2,303	2,118	2,338	2,319	2,410	2,715	2,604	2,831	3,080
Operating profit	387	491	494	444	700	741	691	716	852	818	1,097	1,104	847	621	408	488	504	479	489	731	622	716	743	729	888	890	934	1,255
Operating margin	33.3%	33.9%	35.4%	32.0%	40.5%	42.4%	40.6%	40.1%	43.5%	41.2%	44.0%	43.9%	37.6%	33.5%	23.9%	25.0%	28.3%	25.1%	26.4%	31.7%	29.4%	30.6%	32.0%	30.2%	32.7%	34.2%	33.0%	40.7%
Other income	30	47	42	77	17	14	19	24	36	19	17	52	88	80	114	66	81	86	95	79	79	106	82	119	145	88	155	64
Interest	0	4	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	1	0	3	8	6	6	6
Depreciation	44	46	47	50	56	61	68	70	73	77	80	81	84	86	87	87	93	95	95	95	97	99	99	112	113	118	120	133
Profit before tax	373	488	487	471	661	693	642	669	814	760	1,034	1,076	851	615	436	466	492	469	489	713	604	722	726	733	912	780	963	1,180
Tax	101	131	128	83	169	174	171	167	257	153	131	181	149	122	129	146	136	121	131	175	174	212	137	188	223	197	212	278
Net profit	0	0	0	388	492	520	471	502	559	607	903	895	702	494	307	321	356	348	358	538	430	510	589	545	689	583	751	902
EPS ₹	10.26	13.44	13.53	14.62	18.54	19.57	17.73	18.91	20.99	22.84	33.99	33.70	26.44	18.60	11.56	12.09	13.41	13.11	13.50	20.25	16.20	19.20	22.20	20.49	25.97	21.98	28.31	33.95
Revenue YoY	—	—	—	—	48.8%	21.0%	21.9%	28.7%	13.3%	13.6%	46.5%	40.8%	15.0%	-6.7%	-31.5%	-22.5%	-21.1%	2.9%	8.6%	18.1%	19.1%	22.5%	25.0%	13.8%	16.1%	12.3%	—	27.8%
Profit YoY	—	—	—	—	—	—	—	29.3%	13.6%	16.8%	91.9%	78.2%	25.6%	-18.6%	-66.0%	-64.1%	-49.3%	-29.5%	16.7%	67.6%	20.8%	46.6%	64.5%	26.7%	35.1%	-1.0%	—	65.5%

Earlier results (standalone, Sep '07 – Mar '19)

₹ crore · from BSE, before the NSE XBRL filings begin

Divi's Laboratories Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 10 periods

	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†	FY18†	FY19†
Revenue	947	1,319	1,860	2,129	2,514	3,084	3,721	4,057	3,837	4,880
Operating profit	429	509	710	791	996	1,144	1,396	1,438	1,235	1,800
Operating margin	45.3%	38.6%	38.2%	37.2%	39.6%	37.1%	37.5%	35.4%	32.2%	36.9%
Other income	13	26	51	79	107	61	96	76	128	205
Interest	8	2	4	2	2	2	2	2	2	4
Depreciation	51	53	62	77	92	136	118	123	142	169
Profit before tax	388	479	695	792	1,009	1,067	1,372	1,388	1,219	1,833
Tax	44	43	149	180	217	220	264	335	350	501
Net profit	344	436	546	611	792	847	1,108	1,053	870	1,333

Quarters

showing latest 8 of 46 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†	SEP '18†	DEC '18†	MAR '19†
Revenue	243	284	278	266	334	272	212	226	196	312	265	257	314	482	365	366	417	711	470	474	534	651	517	567	689	741	643	833	791	817	809	964	853	1,095	1,008	1,005	976	1,067	821	890	1,038	1,088	995	1,285	1,343	1,256
Operating profit	105	112	116	110	163	102	79	109	89	152	103	88	123	194	134	138	151	286	192	165	182	252	197	249	288	262	235	307	287	315	300	376	322	398	404	291	381	362	245	277	326	387	352	514	523	411
Operating margin	43.3%	39.4%	41.5%	41.3%	48.8%	37.5%	37.1%	48.3%	45.7%	48.6%	38.8%	34.4%	39.3%	40.3%	36.7%	37.8%	36.2%	40.3%	40.8%	34.8%	34.1%	38.8%	38.1%	43.9%	41.8%	35.4%	36.6%	36.8%	36.3%	38.6%	37.1%	39.0%	37.8%	36.3%	40.1%	29.0%	39.0%	33.9%	29.8%	31.1%	31.4%	35.6%	35.4%	40.0%	39.0%	32.7%
Other income	2	5	4	5	3	3	3	3	4	4	5	6	7	8	10	11	26	4	41	8	22	8	53	37	8	9	13	16	20	13	34	30	15	17	16	20	18	21	30	34	17	48	49	80	35	42
Interest	3	2	2	2	2	2	1	3	2	3	1	1	1	1	0	1	0	3	0	0	0	1	0	0	0	1	0	0	0	1	0	0	0	2	0	0	0	1	0	1	0	0	1	0	3	0
Depreciation	8	9	10	11	12	12	13	13	13	12	13	13	14	13	14	15	16	17	17	19	20	20	21	23	23	25	33	29	29	45	29	30	30	29	30	31	31	31	32	34	37	39	42	42	42	42
Profit before tax	96	106	108	102	152	91	14	96	78	200	94	80	116	188	130	133	160	271	214	154	184	239	229	262	272	245	214	293	278	283	305	375	307	385	390	280	368	350	242	276	306	396	358	552	513	410
Tax	4	5	13	6	14	9	9	10	9	16	8	8	15	13	27	27	38	57	47	36	40	57	55	57	53	52	46	63	57	54	62	80	61	62	88	56	100	91	65	69	81	134	92	154	133	121
Net profit	91	101	94	96	138	82	5	86	69	184	86	73	102	175	103	106	123	215	167	118	144	182	175	205	219	193	168	230	221	229	243	296	247	322	302	224	268	259	177	207	225	262	266	398	379	289
EPS ₹	14.13	15.59	14.62	14.92	21.28	12.73	0.76	6.64	5.28	14.12	6.53	5.52	7.68	13.20	7.74	8.00	9.24	16.19	12.61	8.89	10.86	13.70	13.16	15.44	16.50	14.54	12.65	17.30	16.62	17.25	18.32	11.14	9.29	12.14	11.37	8.43	10.11	9.77	6.65	7.79	8.46	9.85	10.03	14.98	14.29	10.90
Revenue YoY	—	—	—	—	37.6%	-4.2%	-20.3%	-32.1%	-28.0%	—	25.0%	13.4%	60.3%	54.6%	37.5%	42.5%	33.0%	47.5%	28.7%	29.4%	28.0%	-8.5%	10.1%	19.7%	29.0%	13.7%	24.3%	47.0%	14.8%	10.3%	25.8%	15.7%	7.8%	34.1%	24.6%	4.3%	14.5%	-2.6%	-18.5%	-11.5%	6.3%	2.0%	21.2%	44.3%	29.4%	15.5%
Profit YoY	—	—	—	—	50.9%	-18.1%	-94.9%	-37.2%	-16.5%	—	1653.9%	-15.6%	47.7%	-5.1%	18.9%	45.4%	20.6%	22.9%	63.2%	11.2%	17.7%	-15.3%	4.4%	73.7%	51.8%	6.2%	-3.9%	12.1%	0.7%	18.6%	44.8%	28.8%	11.8%	40.8%	24.1%	-24.3%	8.8%	-19.5%	-41.5%	-7.6%	-16.3%	0.9%	50.8%	92.3%	68.9%	10.6%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 22 periods

	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '26	JUN '26
ROE	5.3%	12.0%	19.2%	25.6%	21.3%	22.1%	23.0%	27.7%	25.3%	26.5%	24.7%	19.8%	14.3%	11.6%	10.5%	10.9%	11.8%	12.3%	13.4%	15.1%	15.3%	17.5%
ROCE	24.9%	28.8%	31.5%	33.6%	28.7%	30.3%	31.1%	35.3%	31.4%	31.7%	29.5%	24.5%	18.6%	15.7%	14.7%	15.1%	16.0%	16.8%	18.4%	20.2%	20.4%	23.0%
Net margin	7.2%	14.8%	22.3%	28.5%	28.5%	28.5%	28.7%	31.2%	33.1%	33.6%	32.8%	28.8%	23.5%	20.3%	18.1%	18.5%	20.4%	20.5%	21.3%	22.8%	24.3%	26.0%
EBITDA margin	33.7%	35.7%	38.0%	39.2%	40.9%	41.7%	41.4%	42.3%	43.2%	41.8%	40.2%	35.8%	30.4%	27.7%	25.6%	26.2%	28.1%	28.4%	29.7%	31.0%	32.6%	35.3%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	299.27	351.60	972.74	2244.19	3065.41	3065.72	2975.92	3524.92	4605.38	5724.57	5863.16	5840.00	3536.27	3721.98	1360.93	1546.55	722.00	759.33	843.67	922.67	148.30	148.50
Asset turnover	0.63	0.70	0.73	0.77	0.65	0.67	0.69	0.76	0.67	0.69	0.67	0.62	0.54	0.50	0.51	0.52	0.51	0.53	0.55	0.58	0.53	0.56

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 16 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	SEP '25	MAR '26
Share capital	27	27	53	53	53	53	53	53	53	53	53	53	53	53	53	53
Other equity / reserves	2,963	3,495	4,288	5,304	5,862	6,904	7,257	9,242	11,675	12,082	12,714	12,624	13,518	13,664	15,360	16,708
Total equity	2,990	3,522	4,341	5,357	5,916	6,957	7,310	9,295	11,728	12,135	12,767	12,677	13,571	13,717	15,413	16,761
Borrowings	18	26	42	36	63	106	34	0	0	0	0	2	0	5	89	0
Current liabilities	—	—	—	659	653	847	927	1,112	1,196	914	1,101	1,011	1,278	1,291	1,728	2,043
Non-current liabilities	—	—	—	142	208	234	299	367	451	469	571	595	621	578	1,010	1,229
Total assets	3,710	4,411	4,968	6,159	6,786	8,038	8,536	10,774	13,375	13,518	14,439	14,283	15,470	15,586	18,151	20,033
Property, plant & equipment	1,222	1,305	1,436	1,556	1,990	2,084	2,773	3,695	4,314	4,322	4,714	4,648	4,733	4,652	5,672	6,515
Capital work-in-progress	144	218	264	444	120	492	920	711	470	542	212	496	778	1,316	2,030	2,113
Investments	502	733	803	1,631	1,889	1,946	971	0	72	75	77	80	82	85	67	69
Inventories	932	1,163	1,208	1,320	1,351	1,772	1,864	2,145	2,829	2,970	3,000	2,969	3,184	3,145	3,433	3,954
Receivables	724	742	881	901	1,014	1,163	1,413	1,677	2,424	1,840	1,793	1,858	2,156	2,181	2,614	2,984
Cash & equivalents	41	65	72	21	25	13	43	2,030	1,215	250	170	35	363	38	83	128

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 12 periods

	FY14‡	FY15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY26
Cash from operations	557	826	-0	1,150	776	954	1,216	1,947	1,912	2,460	1,261	2,738
Cash from investing	-305	-521	7	-1,140	-478	-685	-83	75	-2,195	-2,708	-269	-2,219
Cash from financing	-248	-303	-7	2	-314	-246	-1,091	-35	-532	-797	-799	-804
Capex	246	307	—	377	274	733	1,183	910	713	473	1,003	2,520
Free cash flow	310	519	—	774	502	221	33	1,037	1,199	1,987	258	218
Dividends paid	233	311	—	0	319	—	1,024	0	531	796	796	797

Where the assets sit

Mar '26 · ₹ crore

Fixed assets (PPE)

₹6,515 cr33%

CWIP

₹2,113 cr11%

Investments

₹69 cr0%

Inventories

₹3,954 cr20%

Receivables

₹2,984 cr15%

Cash & equivalents

₹128 cr1%

Other assets

₹4,270 cr21%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%

StoxGud checklist: Bullish setup · 8/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+7.6%

6 months+54.0%

1 year+58.5%

3Y CAGR+43.3%

5Y CAGR+16.1%

10Y CAGR+23.3%

50-day avg₹9,404.93

200-day avg₹7,403.01

RSI (14)82

Long-term financials (FY12–FY14)

from published annual reports

Year	Revenue	Profit before tax	Net profit
FY14	₹2,532 Cr	₹991 Cr	₹773 Cr
FY13	₹2,145 Cr	₹781 Cr	₹602 Cr
FY12	₹1,866 Cr	₹681 Cr	₹533 Cr

Years before FY17 follow the older Indian GAAP standard, so they are not exactly comparable with recent years.

Compare Divi's Laboratories Ltd. with

Sun Pharmaceutical Industries vs Divi's Laboratories Divi's Laboratories vs Torrent Pharmaceuticals Divi's Laboratories vs Laurus Labs Divi's Laboratories vs Apollo Hospitals Enterprise

FAQs

What is the share price of Divi's Laboratories Ltd.?

Divi's Laboratories Ltd. (DIVISLAB) closed at ₹10,320.50 on NSE on 06 Nov 2026.

What is the market cap of Divi's Laboratories Ltd.?

₹2,73,493 crore at the latest close.

What is the P/E ratio of Divi's Laboratories Ltd.?

93.5, on trailing-twelve-month earnings from its filings.

How fast is Divi's Laboratories Ltd. growing?

Divi's Laboratories Ltd.: revenue has compounded at 5.6% a year over three years; net profit at -4.6% a year. Latest-quarter revenue is up 27.8% year on year, profit up 65.5%.

How profitable is Divi's Laboratories Ltd.?

On a trailing-twelve-month basis return on equity is 17.5%, return on capital employed 23.0%, operating margin 35.3%, net margin 26.0%.

How much debt does Divi's Laboratories Ltd. have?

Divi's Laboratories Ltd. is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹128 cr (balance sheet of 2026-03-31). Operating profit covers interest 148.5 times.

Financials parsed from Divi's Laboratories Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '19, annual from FY20, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.